Pfizer’s Talzenna Therapy Approved for Use in NHS Scotland
The Scottish Medicines Consortium (SMC) has given the green light to Pfizer’s Talzenna (talazoparib) in combination with enzalutamide for treating metastatic castration-resistant prostate cancer (mCRPC) in patients for whom chemotherapy is not an option. This decision marks a significant step in expanding treatment choices for men battling advanced prostate cancer. A New Hope for Patients The approval means eligible patients in Scotland now have access to a novel therapy that combines a poly ADP-ribose polymerase (PARP) inhibitor with an established treatment. Talazoparib works by disrupting cancer cell DNA repair mechanisms, ultimately leading to their destruction. Oliver Kemp, CEO of Prostate…
